SCHEMBL939151

SCHEMBL939151

Cc1ccc2n[c]oc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.43
MAPT P10636 3/20 0.43
HSD17B10 Q99714 4/20 0.41
NPC1 O15118 7/20 0.38
RAB9A P51151 7/20 0.38
SMN1; SMN2 Q16637 6/20 0.38
ALDH1A1 P00352 6/20 0.38
HPGD P15428 5/20 0.38
NQO2 P16083 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TP53 P04637 3/20 0.37
PKM P14618 1/20 0.37
CYP1A2 P05177 3/20 0.36
USP2 O75604 1/20 0.35
MAPK10 P53779 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938963 0.83 NPC1 (0.42) KDM4EMAPTHSD17B10NPC1RAB9A
SCHEMBL207905 0.75 PIK3CG (0.44) KDM4EMAPTHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL209566 0.75 KDM4E (0.34) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL4150810 0.75 KDM4E (0.42) KDM4EMAPTHSD17B10NPC1RAB9A
SCHEMBL207175 0.75 BACE1 (0.34) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL11784333 0.75 SCN10A (0.36) MAPTHSD17B10NPC1RAB9ASMN1; SMN2
SCHEMBL533256 0.75 ALDH1A1 (0.43) KDM4EMAPTHSD17B10NPC1RAB9A
SCHEMBL11227035 0.74 NQO2 (0.33) KDM4EMAPTNPC1RAB9ANQO2
SCHEMBL407918 0.71 PKM (0.41) KDM4EMEN1KMT2APKMBACE1
SCHEMBL208752 0.71 MAP3K14 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158025-A1 GALACTOKINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH 2023-05-25 US claimed
WO-2021216812-A1 GALACTOKINASE INHIBITORS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2021-10-28 WO claimed
US-10471061-B2 Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-11-12 US claimed
US-20190030031-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS THE US OF AMERICA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) 2019-01-31 US claimed
US-20170035760-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS THE US OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) 2017-02-09 US claimed
US-20140288100-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-09-25 US claimed
WO-2013043192-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-03-28 WO claimed
EP-0093252-B1 THIOMETHYLPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM LUDWIG HEUMANN & CO GMBH (DE) 1988-03-09 EP claimed
US-20230158025-A1 GALACTOKINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH 2023-05-25 US disclosed
CN-108368064-B 1,2, 3-triazole derivative and insecticide and acaricide comprising the same as active ingredient 北兴化学工业株式会社 2022-04-26 CN disclosed
WO-2021216812-A1 GALACTOKINASE INHIBITORS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2021-10-28 WO disclosed
US-11046659-B2 1,2,3-triazole derivative and insecticide and acaricide containing said derivative as active ingredient HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2021-06-29 US disclosed
US-10471061-B2 Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-11-12 US disclosed
US-20190322630-A1 1,2,3-TRIAZOLE DERIVATIVE AND INSECTICIDE AND ACARICIDE CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2019-10-24 US disclosed
WO-2007034251-A1 AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2007-03-29 WO disclosed
WO-2007034253-A1 AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2007-03-29 WO disclosed
US-20070015918-A1 Derivatives of 1,3-diones having a herbicidal activity ISAGRO RICERCA S.R.L (IT) 2007-01-18 US disclosed
EP-1405853-A1 ISOXAZOLINE DERIVATIVES AND HERBICIDES KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2004-04-07 EP disclosed
EP-0093252-B1 THIOMETHYLPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM LUDWIG HEUMANN & CO GMBH (DE) 1988-03-09 EP disclosed
US-4701399-A Photosensitive composition with 2-halomethyl-5-substituted-1,3,4-oxadiazole FUJI PHOTO FILM CO., LTD. (JP) 1987-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190030031-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS GALK1, GALC, GCK KDM4E 3764/4885MAPT 1583/4885HSD17B10 833/4885
US-20140288100-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS GALK1, GALC, B4GALT1 KDM4E 3836/4885MAPT 1680/4885HSD17B10 783/4885
US-20170035760-A1 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS GALK1, GALC, B4GALT1 KDM4E 3757/4885MAPT 1662/4885HSD17B10 786/4885
US-20230158025-A1 GALACTOKINASE INHIBITORS GALK1, GCK, GCKR KDM4E 2218/4885MAPT 2129/4885HSD17B10 2143/4885
US-11046659-B2 1,2,3-triazole derivative and insecticide and acaricide containing said derivative as active ingredient AADAC, CYP51A1, NAT1 KDM4E 1111/4885MAPT 2506/4885HSD17B10 458/4885
US-10471061-B2 Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders GALK1, GALC, GCK KDM4E 3764/4885MAPT 1583/4885HSD17B10 833/4885
US-20190322630-A1 1,2,3-TRIAZOLE DERIVATIVE AND INSECTICIDE AND ACARICIDE CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT AADAC, CYP51A1, NAT1 KDM4E 1111/4885MAPT 2506/4885HSD17B10 458/4885
US-20070015918-A1 Derivatives of 1,3-diones having a herbicidal activity DDT, CYP1B1, CYP51A1 KDM4E 1266/4885MAPT 4135/4885HSD17B10 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.